Abstract |
A pilot study was done using 19 patients with bladder cancer to test the efficacy of cis-diamminedichloroplatinum as a single agent to treat transitional cell carcinoma. Fourteen patients had stage D lesions, 3 patients had stage C and 2 patients had stage B tumors. The patients received 1 mg./kg. cis-diamminedichloroplatinum mixed with 2,000 cc dextrose 5 per cent in one-third normal saline solution, 37.5 gm. mannitol and 40 mEq. potassium chloride. The mixture was given in a slow infusion lasting 6 to 8 hours every week for the first 6 weeks and every 3 weeks thereafter. In the patients with stage D disease 1 complete clinical remission, 7 partial clinical remissions, 1 minimal objective response and 1 subjective response were observed. Four patients did not respond to the treatment. In the 3 stage C patients no response to the drug was observed. In the stage B patients 1 partial remission and 1 minimal objective response were seen. A total objective response (complete remission and partial remission) was seen in 9 of the 19 patients (47 per cent). The duration of the responses varied from 2 to 10 months, with an average of 4.8 months. These promising results seem to indicate the high degree of effectiveness of cis-diamminedichloroplatinum against transitional cell carcinoma of the bladder.
|
Authors | C Merrin |
Journal | The Journal of urology
(J Urol)
Vol. 119
Issue 4
Pg. 493-5
(Apr 1978)
ISSN: 0022-5347 [Print] United States |
PMID | 650753
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Carcinoma, Transitional Cell
(drug therapy, pathology)
- Cisplatin
(administration & dosage, adverse effects, therapeutic use)
- Female
- Humans
- Leukopenia
(chemically induced)
- Male
- Nausea
(chemically induced)
- Neoplasm Metastasis
- Pilot Projects
- Remission, Spontaneous
- Tinnitus
(chemically induced)
- Uric Acid
(blood)
- Urinary Bladder Neoplasms
(drug therapy, pathology)
- Vomiting
(chemically induced)
|